Abstract
A multicenter, double-blind, placebo-controlled study was conducted to investigate the efficacy of an immunostimulant, Ribomunyl, in the prevention of recurrences of infectious rhinitis in adults. This trial involved 327 patients (168 Ribomunyl treated and 159 placebo cases) with an average of 4.3 ± 1.8 rhinitis episodes per patient recorded during the year preceding the study. The main criterion of efficacy was the cumulative number of recurrences of infectious rhinitis during a 6-month follow-up period, as analyzed by standard tests. An additional analysis of relative risk of recurrences used multivariate failure for time data. Ribomunyl was effective throughout the study period, starting from the first month of treatment: a mean of 1.0 ± 1.1 recurrences was recorded in the Ribomunyl group as compared to 1.5 ± 1.4 recurrences in the placebo group; this indicated one-third fewer infections (P = 0.001). The protective effect of Ribomunyl on the relative risk for recurrences was estimated to be 0.58 by multivariate analysis (95% CI: 0.43–0.78,P = 0.0001). Analysis of secondary criteria also favored Ribomunyl: 38.5% less antibiotic courses per patient (0.8 ± 1.3 vs 1.3 ± 1.6;P = 0.002) and the number of days with antibiotics (5.6 ± 9.3 vs 9.1 ± 12.1;P = 0.002).
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Allavana P, Erroi A, Pirelli A, Licciardello L, Mantovani A (1989) Stimulation of cytotoxic and non-cytotoxic functions of natural killer cells by bacterial membrane proteoglycans and ribosomes. Int J Immunopharmacol 11:29–34
Current estimates from the National Health Interview Survey (1993) Vital and Health Statistics; US Department of Health and Human Services. Public Health Service, vol 12, 1994
Faure GC, Béné MC (1995) Use of bacterial immunostimulants in respiratory tract infections. Clin Immunother 4:138–146
Faure GC, Béné MC, Simon C, Quantain A (1990) Increase in specific antibody-forming cells in human tonsils after oral stimulation with D-53, a ribosomal vaccine. Int J Immunopharmacol 12:315–320
International Rhinitis Management Working Group (1994) International Consensus Report on the Diagnosis and Management of Rhinitis. Allergy [Suppl] 19:1–34
Lafont S, Millet I, Kouassi E, Jeannin M, Revillard JP, Normier G, Dussourd d'Hinterland L (1988) Induction of murine B cell proliferation and immunoglobulin synthesis by some bacterial ribosomes. Microbiol Immunol 32:1043–1058
Lambert-Zechovsky N, Bingen E, Salord JC, Proux ML (1984) Epidémiologie des infections ORL et broncho-pulmonaires. Etude de 221 germes dans 202 prélèvements. Gaz Med 91: 11–15
Levenson VJ, Mallett CP, Hale TL (1995) protection against localShigella sonnei infection in mice by parenteral immunization with a nucleoprotein subcellular vaccine. Infect Immun 63:2762–2765
Luini W, De Rossi M, Licciardello L, Colotta F, Mantovani A (1991) Chemotactic cytokine gene expression and production induced in human monocytes by membrane proteoglycans fromKlebsiella pneumoniae. Int J Immunopharmacol 13:631–637
McGhee JR, Mestecky J, Dertzbaugh MT, Eldridge JH, Hirasawa M, Kiyono H (1992) The mucosal immune system: from fundamental concepts to vaccine development. Vaccine 10:75–88
Nikolaeva LV, Savelev EP (1991) Molecular, biological, and immunological properties of ribosomal vaccines. Biomed Sci 2:1–10
Pujol JL, Klein B, Godard P, Dussourd L, Michel FB (1991) Bacterial ribosomal immunostimulants prime alveolar macrophages in vivo to produce interleukin 1 in vitro. Chest 100: 644–648.
Revillard JP, Cozon G, Czerkinsky C (1992) Oral administration of immuno modulateurs and the mucosal immune system. Dev Biol Standard 77:31–37
Roques C, Frayret MN, Luc J, Michel G, Perruchet AM, Cauquil J, Levy D (1991) Effect of an in vivo immunostimulant treatment on PMN functions: interactions with antibiotics in vitro. Int J Immunopharmacol 13:1051–1057
Sironi M, Sica A, Riganti F, Licciardello L, Colotta F, Mantovani A (1990) Interleukine 6 gene expression and production induced in human monocytes by membrane proteoglycans fromKlebsiella pneumoniae. Int J Immunopharmacol 12:397–402
Vautel JM, Cauquil J, Perruchet AM, Thomas AM (1993) Prevention of recurrent ear, nose and throat infections in young children with Ribomunyl: a double blind, placebo-controlled study. Curr Therapeut Res 53:722–729
Wei LJ, Lin DY, Weissfield L (1989) Regression analysis of multivariate incomplete failure time data by modelling marginal distributions. JASA 84:1065–1073
Youmans AS, Youmans GP (1965) Immunogenic activity of a ribosomal fraction obtained fromMycobacterium tuberculosis. J Bacteriol 89:1291–1298
Zanin C, Perrin P, Perruchet AM, Béné MC, Faure GC (1994) Antibody-producing cells in peripheral blood and tonsils after oral treatment of children with bacterial ribosomes. Int J Immunopharmacol 16:497–505
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Serrano, E., Demanez, J.P., Morgon, A. et al. Effectiveness of ribosomal fractions ofKlebsiella pneumoniae, Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae and the membrane fraction ofKp (Ribomunyl) in the prevention of clinical recurrences of infectious rhinitis. Eur Arch Otorhinolaryngol 254, 372–375 (1997). https://doi.org/10.1007/BF01642553
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01642553